CSIMarket
 
Regeneron Pharmaceuticals Inc   (REGN)
Other Ticker:  
 
 
Price: $959.9200 $-4.55 -0.472%
Day's High: $970.71 Week Perf: -1.1 %
Day's Low: $ 959.49 30 Day Perf: 0.54 %
Volume (M): 360 52 Wk High: $ 998.33
Volume (M$): $ 345,859 52 Wk Avg: $826.57
Open: $970.00 52 Wk Low: $684.81



 Market Capitalization (Millions $) 109,150
 Shares Outstanding (Millions) 114
 Employees 10,368
 Revenues (TTM) (Millions $) 13,117
 Net Income (TTM) (Millions $) 3,954
 Cash Flow (TTM) (Millions $) -382
 Capital Exp. (TTM) (Millions $) 719

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc is a biotechnology company that specializes in developing and commercializing innovative medicines for serious medical conditions. The company was established in 1988, and since then it has grown tremendously to become one of the most notable biotech companies in the world.

Regenerones headquarters are based in Tarrytown, New York, where it has a sprawling 579-acre research and development center. The company has over 8,000 employees worldwide, including scientists, researchers, and clinicians, who work tirelessly to advance medical research and develop novel medicines.

Regeneron has a wide portfolio of products that include treatments for a range of conditions such as age-related macular degeneration, diabetic macular edema, atopic dermatitis, asthma, and cancer. The company is known for developing biologics, which are drugs that are made using living organisms. Regenerones proprietary technology and production methods have enabled it to create highly effective and safe biologic treatments that have transformed the lives of many patients.

One of Regenerones most well-known products is Eylea, a drug that treats age-related macular degeneration, a leading cause of blindness in older adults. Regeneron's second drug, Dupixent, is used for the treatment of moderate-to-severe atopic dermatitis in adults.

Regeneron is also active in the fight against COVID-19. The company developed a novel therapy called REGEN-COV, which is a combination of two monoclonal antibodies that have been shown to reduce hospitalization and death in COVID-19 patients. Regeneron has received approvals for this therapy from several regulatory bodies around the world and is now being widely used in the US and other countries.

In conclusion, Regeneron Pharmaceuticals Inc is a pioneering biotechnology company that is committed to developing innovative and effective treatments for serious medical conditions. The company's dedication to research, development, and patient care has made it a leader in the biotech industry and an important player in the fight against diseases.


   Company Address: 777 Old Saw Mill River Road Tarrytown 10591 NY
   Company Phone Number: 847-7000   Stock Exchange / Ticker: NASDAQ REGN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

FDA Approves Praluent for Treating Genetic High Cholesterol in Children, While New Data Shows Encouraging Efficacy in Treating Follicular and Diffuse Large B-cell Lymphomas

Published Mon, Mar 11 2024 11:01 AM UTC

In a significant development, the US Food and Drug Administration (FDA) has expanded its approval of Praluent (alirocumab) injection to include children aged 8 years and older who suffer from heterozygous familial hypercholesterolemia (HeFH), a genetic form of high cholesterol. This breakthrough in treatment options offers hope to the younger population grappling with this p...

Product Service News

EYLEA HD Bolsters Treatment of Sight-Threatening Conditions, While Dupixent's Approval in Japan Offers a Ray of Hope for Chronic Itching Patients

Published Fri, Mar 8 2024 12:00 PM UTC

EYLEA HD: A Breakthrough in the Treatment of Age-related Macular Degeneration and Diabetic Macular Edema, and Japan's Groundbreaking Approval of Dupixent for Chronic Spontaneous Urticaria In a groundbreaking development, the highly anticipated results of the EYLEA HD (aflibercept) Injection 8 mg pivotal data in patients with Wet Age-related Macular Degeneration (wAMD) and Di...

Product Service News

Dupixent (Dupilumab) SBLA Accepted for FDA Priority Review for COPD with Type 2 Inflammation: A Potential Breakthrough in COPD Treatment

Published Fri, Feb 23 2024 6:00 AM UTC

is pleased to present the following article, which provides an overview of the recently accepted supplemental Biologics License Application (sBLA) for Dupixent (Dupilumab) by the U.S. Food and Drug Administration (FDA). This priority review focuses on the potential use of Dupixent for the treatment of chronic obstructive pulmonary disease (COPD) with Type 2 inflammation. T...

Clinical Study

Advancing Treatment Possibilities: Linvoseltamab's BLA for Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Published Wed, Feb 21 2024 12:01 PM UTC

In a promising development, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) recently announced the acceptance of the Biologics License Application (BLA) for linvoseltamab by the U.S. Food and Drug Administration (FDA) for Priority Review. Linvoseltamab is an investigational bispecific antibody specifically designed to address relapsed/refractory (R/R) multiple myeloma (MM) in...

Product Service News

Dupixent Breaks Ground as Japan Approves World's First Treatment for Chronic Spontaneous Urticaria, Offering Relief and Hope for Sufferers

Published Fri, Feb 16 2024 5:59 AM UTC

Japan First in the World to Approve Dupixent (dupilumab) for Chronic Spontaneous Urticaria (CSU)Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo.In a significant breakthrough for chronic spontaneous urticaria (CSU) patients in Japan, the country has become the first in the world to approve Dupixent (dupilumab) for t...






 

Regeneron Pharmaceuticals Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Regeneron Pharmaceuticals Inc does not provide revenue guidance.

Earnings Outlook
Regeneron Pharmaceuticals Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com